Understanding Novel Oral Anticoagulants (NOACs) Webinar Series - PART 1 - 8 August
You need to login to participate in this education.
This education is accredited: RACGP 2 CPD, ACRRM 1 CME PD.
Date: Tuesday 8 August 2017
Time: 6.30-7.30pm AEST
Speaker: Dr Jordan Fulcher
Dr Jordan Fulcher completed his cardiology specialty training at Royal Alfred Hospital in 2013. He completed a Masters in Clinical Trials Research in 2015 and is involved in ongoing research on statins, cholesterol and the risk of cardiovascular disease at the University of Sydney. Dr Fulcher currently works as a VMO cardiologist and is an Honorary VMO at Royal Prince Alfred Hospital. Dr Fulcher has worked regionally in Orange and Coffs Harbour as a locum consultant and VMO cardiologist over the last several years.
The novel oral anticoagulants (NOACs) are as effective and safe as warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF). However, no clinical trials have directly compared these agents with each other. A number of recent observational studies have used real-world data from the USA and Europe to compare the safety and efficacy of individual NOACs.
This webinar discusses the safety and efficacy outcomes for each of the three NOACs available in Australia, what these outcomes mean for choosing a NOAC in your patients, and the role of reversal agents in anticoagulant choice.
This webinar includes an opportunity for all participants to take part in an interactive Q&A with host speaker Dr Jordan Fulcher .
This education is an RACGP accredited activity, supported by Boehringer Ingelheim.
|Novel Oral Anticoagulants (NOACs) Webinar Series - 8 August|
|Novel Oral Anticoagulants (NOACs) Webinar Series Evaluation - 8th August|